GURU.Markets stock price, segment price, and overall market index valuation
The company's share price OBIO
Shares of Orchestra BioMed, a biomedical company with innovative devices, reflect the potential of its technologies to change the standard of care. The price is a bet on successful clinical trials and regulatory approval.
Share prices of companies in the market segment - Specialized medical equipment
Orchestra BioMed develops and commercializes therapeutic devices for the treatment of cardiovascular diseases such as hypertension and atherosclerosis. We classify it as an innovator in the Specialized Medical Equipment segment. The chart below shows the overall dynamics of this high-tech medical sector.
Broad Market Index - GURU.Markets
Orchestra BioMed is a biomedical company developing therapeutic devices for the treatment of arrhythmia and hypertension. Its innovativeness earns it a place in the GURU.Markets index. The chart below compares its performance with the overall market.
Change in the price of a company, segment, and market as a whole per day
OBIO - Daily change in the company's share price OBIO
The daily price change of Orchestra BioMed, a developer of innovative medical equipment, reflects the inherent volatility of the sector. This indicator measures sensitivity to news about clinical trials and partnerships, and is a key component in the valuation formulas on System.GURU.Markets.
Daily change in the price of a set of shares in a market segment - Specialized medical equipment
Orchestra BioMed Holdings, Inc. is a medical device company. This chart illustrates the high volatility of the MedTech industry. Comparing it to OBIO, which focuses on cardiology, helps assess the extent to which its innovative products contribute to its volatility.
Daily change in the price of a broad market stock, index - GURU.Markets
Orchestra BioMed develops innovative therapeutic devices at the intersection of medicine and engineering. The company's stock reflects progress in medical technology and investor expectations for new technologies. Its performance reflects the medical innovation sector's contribution to the overall stock market.
Dynamics of market capitalization of the company, segment and the market as a whole over 12 months
Annual dynamics of the company's market capitalization OBIO
Orchestra BioMed's year-over-year performance tells the story of its unique model for developing innovative medical devices. Its 12-month market cap reflects progress in its key programs—a pacemaker for heart rhythm modulation and a renal denervation catheter. Partnerships with giants like Medtronic confirm its potential.
Annual dynamics of market capitalization of the market segment - Specialized medical equipment
Orchestra BioMed, as a therapeutic device company, is betting on medical innovation. Its performance relative to the sector will reveal the extent to which investors believe in its ability to commercialize its unique technologies for treating cardiovascular diseases.
Annual dynamics of market capitalization of broad market stocks, index - GURU.Markets
Orchestra BioMed, with its unique partnership model for developing medical technology devices, is a niche company. Its stock price is unaffected by the economy, but rather by its success in securing deals with industry giants. The price action is a bet on the success of its innovative approach to R&D.
Dynamics of market capitalization of the company, segment and the market as a whole for the month
Monthly dynamics of the company's market capitalization OBIO
Orchestra BioMed develops innovative medical devices, often in partnership with industry leaders. Its monthly performance reflects the achievement of key development milestones. News of successful clinical trials or progress in partnerships (for example, with Medtronic) boosts investor confidence.
Monthly dynamics of market capitalization of the market segment - Specialized medical equipment
Orchestra BioMed develops therapeutic devices for the treatment of arrhythmia and hypertension that can be implanted during standard cardiac procedures. The graph below shows the overall dynamics in the medical device sector, reflecting the demand for innovations that improve cardiovascular treatment outcomes.
Monthly dynamics of market capitalization of broad market stocks, index - GURU.Markets
Shares of medical companies with breakthrough but not yet fully adopted technology are extremely volatile. The chart below shows the overall risk appetite. Is Orchestra BioMed moving at its own pace, driven by news of partnerships and clinical data?
Dynamics of market capitalization of the company, segment and the market as a whole for the week
Weekly dynamics of the company's market capitalization OBIO
Orchestra BioMed's weekly performance reflects innovation in cardiology. This company, which develops therapeutic devices for the treatment of arrhythmia and hypertension, is responding to clinical trial data and partnerships with medical device manufacturers.
Weekly dynamics of market capitalization of the market segment - Specialized medical equipment
Orchestra BioMed develops innovative medical devices for cardiology. The company's success depends on regulatory approval and the acceptance of its technologies by the medical community. The chart below shows whether Orchestra BioMed's stock price fluctuations reflect the company's unique achievements or general trends in the specialized medical equipment sector.
Weekly dynamics of market capitalization of stocks of the broad market, index - GURU.Markets
Orchestra BioMed develops innovative medical devices. Demand for its products is driven by medical needs. The chart below will help you determine whether OBIO shares are truly a "safe haven" asset, demonstrating stability amid market uncertainty.
Market capitalization of the company, segment and market as a whole
OBIO - Market capitalization of the company OBIO
Orchestra BioMed's market capitalization chart tells the story of an innovative company that develops medical devices and then seeks partnerships among industry giants for their commercialization. Its dynamics reflect its successes in developing, for example, a pacemaker that modulates blood pressure. Its trajectory is an assessment of its unique business model.
OBIO - Share of the company's market capitalization OBIO within the market segment - Specialized medical equipment
Orchestra BioMed develops therapeutic devices for the treatment of arrhythmia and hypertension. Its market capitalization reflects the potential of its innovative technologies to improve existing medical procedures. The chart shows how the market assesses its chances of implementing its developments into widespread clinical practice.
Market capitalization of the market segment - Specialized medical equipment
Orchestra BioMed develops innovative medical devices for cardiology. The chart below shows the total market capitalization of this high-tech sector. Its growth reflects the ongoing need for new, more effective treatments for cardiovascular diseases.
Market capitalization of all companies included in a broad market index - GURU.Markets
Orchestra BioMed develops innovative medical devices, such as those for cardiology. The market capitalization of such companies is a bet that their technologies will transform medical practice. Their performance on the overall chart reflects how investors assess the potential of new health gadgets.
Book value capitalization of the company, segment and market as a whole
OBIO - Book value capitalization of the company OBIO
Orchestra BioMed's balance sheet consists of its capital and a portfolio of patents for innovative medical devices, such as a pacemaker that simultaneously delivers medication. This provides the tangible, scientific foundation for the creation of "smart" implants. How has this unique medical technology asset evolved? The chart below shows its dynamics.
OBIO - Share of the company's book capitalization OBIO within the market segment - Specialized medical equipment
Orchestra BioMed develops innovative medical devices, such as drug-delivering pacemakers. The chart shows the proportion of its R&D and manufacturing assets, reflecting the physical foundation upon which its combination therapeutic solutions are created.
Market segment balance sheet capitalization - Specialized medical equipment
Orchestra BioMed develops innovative medical devices. This requires both robust R&D and manufacturing capabilities to create complex instruments. The book value chart shows the real assets behind its cutting-edge therapeutic solutions.
Book value of all companies included in the broad market index - GURU.Markets
Orchestra BioMed develops innovative medical devices. Its book value represents its R&D centers, testing laboratories, and clinical trial capital. The chart shows the resources used to create breakthrough technologies for cardiology and other medical fields.
The ratio of market capitalization to book capitalization of a company, segment, and the market as a whole
Market capitalization to book capitalization ratio - OBIO
Orchestra BioMed is an innovative company. Its value lies not in its assets, but in its unique business model of partnering with giants like Medtronic. The chart shows the premium the market pays for its ability to bring breakthrough ideas to market through strong partners.
Market to book capitalization ratio in a market segment - Specialized medical equipment
Orchestra BioMed develops therapeutic devices for the treatment of arrhythmia and hypertension. Its innovative model includes partnerships with major medical device manufacturers. The chart shows how the market perceives its unique approach and the potential of its technologies.
Market to book capitalization ratio for the market as a whole
Orchestra BioMed develops innovative medical devices, such as a pacemaker that can simultaneously treat hypertension. The company's value lies in its breakthrough engineering solutions. This chart shows the overall valuation, but how do investors value a company that aims to combine multiple treatment modalities into a single implantable device?
Debts of the company, segment and market as a whole
OBIO - Company debts OBIO
Orchestra BioMed has an innovative business model: it develops medical devices to a certain stage and then partners with industry giants. This chart shows how the company finances this capital-efficient strategy, developing its technologies to a point of appeal to major players.
Market segment debts - Specialized medical equipment
Orchestra BioMed develops therapeutic devices for the treatment of arrhythmia and hypertension. Bringing complex medical devices to market is a long process, requiring regulatory approval. This chart shows how the company funds its clinical programs and engineering development in the competitive medical device sector.
Market debt in general
Debt to book value of the company, segment and market as a whole
The company's debt to book capitalization ratio OBIO
Orchestra BioMed develops innovative medical devices for cardiology. This chart shows how the company finances its long and expensive journey from concept to regulatory approval and market entry. The level of debt reflects the stage of development and investor confidence in the potential of its technologies to transform clinical practice.
Market segment debt to market segment book capitalization - Specialized medical equipment
Orchestra BioMed develops therapeutic devices for the treatment of arrhythmia and hypertension. This chart shows the overall debt burden in the specialized medical device sector. It allows one to assess how companies in this niche finance their lengthy development and clinical trial cycles, and how Orchestra BioMed manages its balance sheet.
Debt to book value of all companies in the market
Orchestra BioMed develops and commercializes therapeutic devices for cardiology. This intersection of technology and medicine requires investment in both R&D and manufacturing. The market's overall debt burden chart provides context, allowing one to assess the type of financing—debt or equity—the company chooses to bring its products to market.
P/E of the company, segment and market as a whole
P/E - OBIO
This chart for Orchestra BioMed, a company developing innovative medical devices, shows the valuation of its therapeutic solutions. The multiple reflects investors' confidence in the potential of its flagship products in cardiology and hypertension, as well as the value of its partnership strategy with major players in the medical industry.
P/E of the market segment - Specialized medical equipment
Orchestra BioMed's medical devices and pharmaceuticals business is a hybrid model. This chart shows the average valuation for healthcare companies. It helps to understand that Orchestra, with its unique strategy of developing combination therapies (device and drug), is valued based on the potential of this synergistic approach.
P/E of the market as a whole
Orchestra BioMed develops therapeutic devices for the treatment of arrhythmia and hypertension that can be implanted during standard procedures. This innovative approach to treating common conditions is a key component of the market. This chart, showing the overall market temperature, helps us understand whether Orchestra BioMed is valued for its breakthrough potential or whether its valuation is simply following medical technology trends.
Future P/E of the company, segment and market as a whole
Future (projected) P/E of the company OBIO
Orchestra BioMed develops therapeutic devices for the treatment of arrhythmia and hypertension. This chart reflects investor expectations for its innovative products, which combine drug and device therapy. The trendline estimates the likelihood of regulatory approval and commercial success.
%20P%2FE%20OBIO&width=1500&height=450&colorIndex=35&filename=GURU_Markets_-_Chart-of-the-companys-future-projected-PE-OBIO&v=1772512095809 "Chart of the company's future (projected) P/E OBIO")
Future (projected) P/E of the market segment - Specialized medical equipment
Orchestra BioMed develops therapeutic devices for the treatment of arrhythmia and hypertension. This chart shows average profitability expectations for the medical device sector. It provides insight into how the market values the company's innovative approaches to treating common cardiovascular diseases and its partnership strategy.
%20P%2FE%20graph%20of%20the%20market%20segment%20-%20Specialized%20medical%20equipment&width=1500&height=450&colorIndex=36&filename=GURU_Markets_-_Future-projected-PE-graph-of-the-market-segment-Specialized-medical-equipment&v=1772512095817 "Future (projected) P/E graph of the market segment - Specialized medical equipment")
Future (projected) P/E of the market as a whole
Orchestra BioMed develops therapeutic devices for the treatment of arrhythmia and hypertension. This chart reflects sentiment in the healthcare sector. For a company creating innovative medical devices that could change the standard of cardiovascular treatment, it reflects the market's confidence in the potential of new technologies in this field.
%20P%2FE%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=37&filename=GURU_Markets_-_Chart-of-the-future-projected-PE-of-the-market-as-a-whole&v=1772512095823 "Chart of the future (projected) P/E of the market as a whole")
Profit of the company, segment and market as a whole
Company profit OBIO
Orchestra BioMed develops therapeutic devices for the treatment of arrhythmia and hypertension. The financial results illustrated in this chart reflect the investment in research and clinical trials to bring these innovative products to market. They demonstrate the cost of creating new medical technologies that have the potential to improve the lives of millions of patients.
Profit of companies in the market segment - Specialized medical equipment
Orchestra BioMed develops therapeutic devices for the treatment of arrhythmia and hypertension. Its flagship products are aimed at improving the outcomes of standard medical procedures. This chart illustrates how innovations in medical devices can improve treatment effectiveness and create new standards, impacting overall profitability in the medical device sector.
Overall market profit
Orchestra BioMed develops innovative medical devices, including those for cardiology. The company's business model often involves partnerships with major medical equipment manufacturers. The success of such projects depends on the willingness of industry giants to invest in new technologies, which, in turn, is linked to their financial health and the overall health of the economy.
Future (predicted) profit of the company, segment and market as a whole
Future (projected) profit of the company OBIO
Orchestra BioMed develops therapeutic devices for the treatment of atherosclerosis and hypertension. The profit/loss forecast shown in the graph reflects analysts' expectations for clinical trials and future partnerships with major medical device manufacturers to bring its technologies to market.
%20profit%20of%20the%20company%20OBIO&width=1500&height=450&colorIndex=41&filename=GURU_Markets_-_Graph-of-future-projected-profit-of-the-company-OBIO&v=1772512095855 "Graph of future (projected) profit of the company OBIO")
Future (predicted) profit of companies in the market segment - Specialized medical equipment
Orchestra BioMed develops therapeutic devices for the treatment of arrhythmia and hypertension, combining medical implants with simultaneous drug delivery. This is an innovative approach. This chart shows the revenue forecast for the specialized medical device sector, allowing one to assess the market's perception of the potential of Orchestra BioMed's unique platform.
%20profits%20of%20companies%20in%20a%20market%20segment%20-%20Specialized%20medical%20equipment&width=1500&height=450&colorIndex=42&filename=GURU_Markets_-_Graph-of-future-predicted-profits-of-companies-in-a-market-segment-Specialized-medical-equipment&v=1772512095863 "Graph of future (predicted) profits of companies in a market segment - Specialized medical equipment")
Future (predicted) profit of the market as a whole
Orchestra BioMed develops innovative medical devices, including those for cardiology. The company's success depends on the results of clinical trials and partnerships. This schedule, reflecting the state of the market, influences the willingness of large medical companies to invest in new technologies and the availability of financing.
%20profits%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=43&filename=GURU_Markets_-_Chart-of-future-predicted-profits-of-the-market-as-a-whole&v=1772512095871 "Chart of future (predicted) profits of the market as a whole")
P/S of the company, segment and market as a whole
P/S - OBIO
Orchestra BioMed develops innovative medical devices for cardiology, such as a drug-eluting stent that delivers medication for hypertension control. This chart reflects investor expectations for its breakthrough technologies. The valuation is a bet on the commercial success of its multifunctional devices.
P/S market segment - Specialized medical equipment
Orchestra BioMed develops therapeutic devices for the treatment of atherosclerosis and heart rhythm disorders, combining them with existing drugs to enhance effectiveness. This chart shows the average price-to-sales ratio for the medical device sector. It reflects how investors view the company's innovative approach to treating cardiovascular diseases.
P/S of the market as a whole
Orchestra BioMed develops and commercializes therapeutic devices for the treatment of cardiovascular diseases, including unique cardiac pacing technology and drug-eluting stents. This chart shows how the market values companies creating innovative medical devices that can improve treatment outcomes for millions of patients.
Future P/S of the company, segment and market as a whole
Future (projected) P/S of the company OBIO
Orchestra BioMed develops therapeutic devices for the treatment of cardiovascular diseases. This chart shows the company's valuation relative to its projected future sales. It reflects investor expectations for the success of its innovative products, such as its pacemaker with heart rate modulation.
%20P%2FS%20OBIO&width=1500&height=450&colorIndex=47&filename=GURU_Markets_-_The-graph-of-the-companys-future-projected-PS-OBIO&v=1772512095882 "The graph of the company's future (projected) P/S OBIO")
Future (projected) P/S of the market segment - Specialized medical equipment
Orchestra BioMed develops therapeutic devices for the treatment of arrhythmia and hypertension. The company's innovative approach involves modulating bioelectronic signals. This chart reflects investor expectations for its advanced technologies and potential future revenue compared to other medical device manufacturers.
%20P%2FS%20market%20segment%20graph%20-%20Specialized%20medical%20equipment&width=1500&height=450&colorIndex=48&filename=GURU_Markets_-_Future-projected-PS-market-segment-graph-Specialized-medical-equipment&v=1772512095888 "Future (projected) P/S market segment graph - Specialized medical equipment")
Future (projected) P/S of the market as a whole
Orchestra BioMed develops therapeutic devices for the treatment of arrhythmia and hypertension. The company's future depends on the success of clinical trials and regulatory approval. This general expectations chart for OBIO is not a direct driver. Demand for its technologies is determined by medical needs, which are independent of the overall economic situation.
%20P%2FS%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=49&filename=GURU_Markets_-_Chart-of-the-future-projected-PS-of-the-market-as-a-whole&v=1772512095901 "Chart of the future (projected) P/S of the market as a whole")
Sales of the company, segment and market as a whole
Company sales OBIO
This chart illustrates an innovative business model in the medical technology industry. For Orchestra BioMed, it reflects revenue from upfront and milestone payments from partners. The company develops cutting-edge therapeutic devices and then collaborates with industry leaders to commercialize them.
Sales of companies in the market segment - Specialized medical equipment
Orchestra BioMed develops therapeutic devices for the treatment of arrhythmia and hypertension. Its innovative products have the potential to change treatment standards. This chart shows revenue for the medical device sector. Successful commercialization of Orchestra BioMed's technologies, such as the cardiac implant, will significantly contribute to the growth of the overall market.
Overall market sales
Orchestra BioMed develops innovative medical devices for cardiology. Its flagship products are aimed at improving the results of hypertension and arrhythmia treatments. The company's success depends on the implementation of its technologies in clinical practice and is an indicator of progress in the medical device sector.
Future sales volume of the company, segment and market as a whole
Future (projected) sales of the company OBIO
Orchestra BioMed develops innovative medical devices for cardiology, including a pacemaker with heart rate modulation. The company's future sales depend on the success of clinical trials and partnerships with market leaders.
%20sales%20of%20the%20company%20OBIO&width=1500&height=450&colorIndex=53&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-the-company-OBIO&v=1772512095917 "Schedule of future (projected) sales of the company OBIO")
Future (projected) sales of companies in the market segment - Specialized medical equipment
Orchestra BioMed develops therapeutic devices for the treatment of arrhythmia and hypertension. The forecast for the specialized medical equipment sector demonstrates the demand for innovation in cardiology. It reflects the significant need for new treatments for common cardiovascular diseases.
%20sales%20of%20companies%20in%20the%20market%20segment%20-%20Specialized%20medical%20equipment&width=1500&height=450&colorIndex=54&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-companies-in-the-market-segment-Specialized-medical-equipment&v=1772512095926 "Schedule of future (projected) sales of companies in the market segment - Specialized medical equipment")
Future (projected) sales of the market as a whole
Orchestra BioMed develops and commercializes therapeutic devices for the treatment of arrhythmia and hypertension. Demand for its products will be determined by medical needs and the effectiveness of the devices. This general economic activity schedule impacts hospital budgets and their ability to purchase new, innovative medical equipment, which is essential for commercialization.
%20sales%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=55&filename=GURU_Markets_-_Schedule-of-future-predicted-sales-of-the-market-as-a-whole&v=1772512095928 "Schedule of future (predicted) sales of the market as a whole")
Marginality of the company, segment and market as a whole
Company marginality OBIO
Orchestra BioMed develops and commercializes innovative medical devices for cardiology. Its business model is based on partnerships with leading medical device manufacturers. This chart shows how the company balances R&D expenditures with receiving milestone payments from partners on the path to full commercialization.
Market segment marginality - Specialized medical equipment
Orchestra BioMed develops therapeutic devices for the treatment of arrhythmia and hypertension. Its business model is based on partnerships with major medical device manufacturers to bring its products to market. This chart illustrates the operational structure of this innovative collaboration model compared to traditional medtech companies.
Market marginality as a whole
Orchestra BioMed Holdings, Inc. is a biomedical company developing therapeutic devices for the treatment of arrhythmia and hypertension. This chart shows the company's overall profit margin. It illustrates Orchestra BioMed's partnership business model. The company strives for profitability by co-developing technologies with leaders in the medical device industry.
Employees in the company, segment and market as a whole
Number of employees in the company OBIO
Orchestra BioMed develops innovative medical devices for cardiology. Its business model is based on partnerships with large companies. The small staff, shown in this graph, consists of key engineers and managers, while development and commercialization are outsourced to partners, making it capital-efficient.
Share of the company's employees OBIO within the market segment - Specialized medical equipment
Orchestra BioMed develops innovative medical devices for cardiology, such as a pacemaker with contractility modulation. This chart shows its engineering specialization. It reflects the proportion of medical engineers and clinical specialists in the narrow field of interventional cardiology and arrhythmology that Orchestra attracts.
Number of employees in the market segment - Specialized medical equipment
Orchestra BioMed develops therapeutic devices for the treatment of arrhythmia and hypertension. This chart illustrates innovation in the medical technology (MedTech) sector. The growing team of engineers and clinicians here signifies progress in creating devices that can not only treat but also improve the effectiveness of existing medications.
Number of employees in the market as a whole
Orchestra BioMed develops innovative medical devices, combining them with existing drugs. Their business model is based on partnerships with major market players. This overall workload is less important to them than successful clinical data. Positive trial results pave the way for strategic deals, which drive the company's growth.
Market capitalization per employee (in thousands of dollars) of the company, segment, and market as a whole
Market capitalization per employee (in thousands of dollars) of the company OBIO (OBIO)
Orchestra BioMed develops innovative medical devices for cardiology, including those for lowering blood pressure and improving stenting outcomes. This chart shows how the market values the medical technology company. The high market capitalization per employee reflects the value of its intellectual property and the potential of its therapeutic devices to transform treatment standards.
%20of%20the%20company%20OBIO%20(OBIO)&width=1500&height=450&colorIndex=63&filename=GURU_Markets_-_Chart-of-market-capitalization-per-employee-in-thousands-of-dollars-of-the-company-OBIO-OBIO&v=1772512095967 "Chart of market capitalization per employee (in thousands of dollars) of the company OBIO (OBIO)")
Market capitalization per employee (in thousands of dollars) in the market segment - Specialized medical equipment
Orchestra BioMed develops innovative medical devices, often in partnership with large companies. This allows it to remain lean while focusing on R&D. This chart demonstrates the effectiveness of this model: the company can achieve high valuation thanks to its patents without inflating its staff, which is reflected in its high per-employee ratio.
%20by%20market%20segment%20-%20Specialized%20medical%20equipment&width=1500&height=450&colorIndex=64&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-by-market-segment-Specialized-medical-equipment&v=1772512095976 "Market capitalization per employee (in thousands of dollars) by market segment - Specialized medical equipment")
Market capitalization per employee (in thousands of dollars) for the overall market
Orchestra BioMed develops therapeutic devices for the treatment of arrhythmia and hypertension. This chart reflects the high employee rating typical for MedTech companies, where innovative devices can significantly improve treatment outcomes and become standard medical practice.
%20for%20the%20overall%20market&width=1500&height=450&colorIndex=65&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-for-the-overall-market&v=1772512095977 "Market capitalization per employee (in thousands of dollars) for the overall market")
Profit per employee (in thousands of dollars) for the company, segment, and market as a whole
Profit per employee (in thousands of dollars) of the company OBIO (OBIO)
Orchestra BioMed is a biotech company with a "hybrid" model. They develop both drugs (for hypertension) and medical devices (drug-eluting pacemakers) and are committed to partnerships. This chart shows how effective this R&D model is. It measures how much profit (from partnerships) or loss (from R&D) each of their engineers and scientists generates.
%20Chart%20OBIO%20(OBIO)&width=1500&height=450&colorIndex=66&filename=GURU_Markets_-_Company-Profit-Per-Employee-in-thousands-of-dollars-Chart-OBIO-OBIO&v=1772512095980 "Company Profit Per Employee (in thousands of dollars) Chart OBIO (OBIO)")
Profit per employee (in thousands of dollars) in the market segment - Specialized medical equipment
Orchestra BioMed (OBIO) develops therapeutic solutions for the cardiovascular system. This chart, which represents the industry benchmark, is OBIO's goal. The company is working on innovative products (for example, for hypertension management). Their effectiveness will be measured by the ability to successfully complete clinical trials and bring high-margin products to market.
%20in%20the%20market%20segment%20-%20Specialized%20medical%20equipment&width=1500&height=450&colorIndex=67&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-in-the-market-segment-Specialized-medical-equipment&v=1772512095986 "Chart of profit per employee (in thousands of dollars) in the market segment - Specialized medical equipment")
Profit per employee (in thousands of dollars) for the market as a whole
Orchestra BioMed develops innovative medical devices, particularly for cardiology. It is a MedTech company in the development stage. As in biotech, its profit per employee is likely negative. The chart shows how much the company invests in engineers and doctors to bring its complex therapeutic devices to commercialization.
%20for%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=68&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-for-the-market-as-a-whole&v=1772512095989 "Chart of profit per employee (in thousands of dollars) for the market as a whole")
Sales to employees of the company, segment and market as a whole
Sales per company employee OBIO (OBIO)
Orchestra BioMed develops therapeutic devices for cardiology. This chart reflects its business model, which is often based on partnerships. Revenue may come from milestone payments as development progresses. This metric demonstrates the company's ability to advance its innovations to commercialization with a relatively small team.
&width=1500&height=450&colorIndex=69&filename=GURU_Markets_-_Sales-chart-per-company-employee-OBIO-OBIO&v=1772512095996 "Sales chart per company employee OBIO (OBIO)")
Sales per employee in the market segment - Specialized medical equipment
Orchestra BioMed develops therapeutic devices for the treatment of cardiovascular diseases (e.g., a pacemaker for hypertension). Their model is partnerships with leaders (like Medtronic). This metric reflects how effectively their R&D team generates revenue (milestone payments, royalties) from these strategic partnerships.
Sales per employee for the market as a whole
Orchestra BioMed develops innovative medical devices, such as a "modulating pacemaker" and a "drug-eluting coronary stent." Their model is partnerships with major players. This chart shows revenue per employee. It reflects R&D payments from partners, not sales. This is an indicator of the effectiveness of their R&D model: how much revenue their small team of engineers generates.
Short shares by company, segment and market as a whole
Shares shorted by company OBIO (OBIO)
Orchestra BioMed develops therapeutic device candidates, including for cardiology (e.g., drug-eluting stents) and neurology. This chart shows bearish bets. Bearish bets may doubt that these complex devices will receive regulatory approval (e.g., the FDA) or that they will be able to prove their superiority over existing treatments.
&width=1500&height=450&colorIndex=72&filename=GURU_Markets_-_Short-Shares-Chart-for-the-Company-OBIO-OBIO&v=1772512096018 "Short Shares Chart for the Company OBIO (OBIO)")
Shares shorted by market segment - Specialized medical equipment
Orchestra BioMed develops therapeutic devices for the treatment of arrhythmia and hypertension. This chart shows overall short positions in the medical device sector. If it's high, investors may be concerned that hospitals are cutting their budgets for new equipment purchases or that regulators (like the FDA) are tightening requirements for new devices.
Shares shorted by the overall market
Orchestra BioMed (OBIO) is a clinical-stage company developing innovative medical devices. This is a speculative R&D story. When this general fear indicator rises, investors immediately "flee risk." They sell off unprofitable, R&D-focused companies like OBIO, which are unprofitable.
RSI 14 indicator for a company, segment, and market as a whole
The company's RSI 14 indicator OBIO (OBIO)
Orchestra BioMed develops innovative medical devices. The stock is speculative and dependent on R&D and approvals. A chart reading above 70 may reflect positive news about trials or approvals. Oversold levels (<30) are often associated with delays, setbacks, or general investor risk aversion.
&width=1500&height=450&colorIndex=75&filename=GURU_Markets_-_RSI-14-indicator-chart-for-the-companys-stock-OBIO-OBIO&v=1772512096040 "RSI 14 indicator chart for the company's stock OBIO (OBIO)")
RSI 14 Market Segment - Specialized medical equipment
Orchestra (OBIO) is a "hybrid" medtech. They combine a "drug" and a "device," such as a pacemaker that treats hypertension. The RSI_14_Seg for their segment (medtech) shows whether the sector is overbought. This helps us determine whether OBIO's growth is their niche or a general sign of overheating.
RSI 14 for the overall market
Orchestra BioMed (OBIO) is a biotech company. Like everything in its sector, it's critically dependent on this schedule. Market euphoria offers the potential to easily raise hundreds of millions of dollars for research. Market panic risks running out of money before its breakthrough technologies reach patients.
Analyst consensus forecast for the company's share price, the segment, and the market as a whole
Analyst consensus stock price forecast OBIO (OBIO)
Orchestra BioMed develops therapeutic devices for cardiology. Their key products are the BackBeat pacemaker and the Virtue catheter for treating hypertension. This chart shows the analysts' average 12-month forecast, reflecting their assessment of the likelihood of clinical trial success and approval for these innovative devices.
&width=1500&height=450&colorIndex=78&filename=GURU_Markets_-_A-chart-showing-analyst-consensus-forecasts-for-the-expected-stock-price.-OBIO-OBIO&v=1772512096067 "A chart showing analyst consensus forecasts for the expected stock price. OBIO (OBIO)")
The difference between the consensus estimate and the actual stock price OBIO (OBIO)
Orchestra BioMed (OBIO) is a medtech company developing hybrid solutions (drug and device), for example, in cardiology. This chart shows the valuation of their platform. It measures the gap between the price and the consensus target, reflecting the high, yet speculative, potential analysts see in their R&D pipeline and partnerships.
&width=1500&height=450&colorIndex=79&filename=GURU_Markets_-_A-chart-showing-the-difference-between-the-consensus-forecast-and-the-actual-stock-price.-OBIO-OBIO&v=1772512096073 "A chart showing the difference between the consensus forecast and the actual stock price. OBIO (OBIO)")
Analyst consensus forecast for stock prices by market segment - Specialized medical equipment
Orchestra BioMed is a biotech company developing biotherapeutic devices, specifically drug-eluting stents for the treatment of arrhythmia and hypertension. This chart shows general expectations for the specialized medical equipment sector. It reflects whether experts believe in hybrid "drug-device" devices.
Analysts' consensus forecast for the overall market share price
Orchestra BioMed develops biotherapeutic devices. Their flagship products are a drug-delivering pacemaker and stents for treating blood pressure. This chart shows the overall risk appetite. For Orchestra, a company with breakthrough but challenging-to-approval products, overall market optimism is important for funding the lengthy clinical and regulatory processes.
AKIMA index of the company, segment and market as a whole
AKiMA Company Index OBIO
Orchestra BioMed is an innovation incubator. They don't have a single product; they develop a portfolio of breakthrough MedTech solutions (for cardiology and neurology), which they then license or sell to major strategic partners. This chart is a summary indicator of their R&D portfolio. It reflects their ability to create value by bringing technologies to proof of concept and securing lucrative deals.
AKIMA Market Segment Index - Specialized medical equipment
Orchestra BioMed develops therapeutic devices for the treatment of cardiovascular diseases, including a unique drug-delivery pacemaker. This chart shows the average index for the specialized medical device sector. It helps assess how Orchestra BioMed's innovative business model compares to the industry average.
The AKIM Index for the overall market
Orchestra BioMed is a biomedical innovation company operating under a partnership model (Medtronic, Terumo) to develop devices for hypertension and atherosclerosis. This chart, reflecting the market average, is a backdrop. It helps assess how this R&D risk-reduction model compares to overall macroeconomic trends.
